AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease flares in COPD.

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that affects millions of people in the United States and around the world. Despite its prevalence, many individuals ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. After things have been stable for a long ...

Biomedical startups are taking aim at a deadly lung condition that has long lacked innovative treatments. Chronic obstructive pulmonary disease, caused by smoking and air pollution, hinders breathing ...

Chronic Obstructive Pulmonary Disease (COPD) is a chronic and irreversible lung condition that is a global public health problem. Globally, approximately 213 million people have COPD, and it was ...

Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for about three months, a new study has revealed. This research by The University ...